Abstract
Subcutaneous Epcoritamab in Combination with R 2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have